EW Weekly, October 2, 2020

- FDA approves preservative-free antihistamine drop
- FDA accepts IND for dry eye drop
- First patient dosed in Phase 2 clinical trial for cyclosporine intracanalicular insert
- Orphan drug designation granted for treatment of Leber hereditary optic neuropathy
- New program launched for development of presbyopia-correcting eye drop
- Product News
- Researchers who sought to describe and summarize outcomes of randomized controlled trials of multifocal vs. monofocal IOLs concluded that a core outcome set is needed because there is “considerable heterogeneity in the collection and reporting” on this topic in medical literature. This results in difficulty to estimate the effect and it “is a potential source of research waste,” the investigators wrote. All randomized controlled trials of multifocal vs. monofocal lenses in a Cochrane review were identified. Half of the studies reported data as a continuous measure, one-third reported as continuous and categorical measures, and a small number reported only categorical measures. The researchers also noted little consensus for study cut points. The study authors propose an initial core outcome set that could be used in studies going forward. This paper was published in the British Journal of Ophthalmology.
- With a mean wait time of 153 days (plus or minus 101 days) for crosslinking, 39.6% of eyes were found to progress in a prospective observational study of 96 eyes of 96 patients with keratoconus. The researchers observed significant differences in index of surface variance, index of vertical asymmetry, keratoconus index, and index of height decentration in eyes that progressed during this wait time vs. those that remained stable. They did not see significant differences in steepest keratometry, average keratometry, cornea thinnest point, or center keratoconus index. Age, atopy/atopic keratoconjunctivitis, eye rubbing, and wait time were not significant risk factors for progression, but Maori ethnicity was determined a risk factor. The authors concluded that risk stratification for patients waiting for crosslinking could reduce risk of progression during this timeframe. The research is published in the journal Cornea.
- Johnson & Johnson Vision launched the TECNIS Synergy Toric II, a continuous range of vision and astigmatism-correcting IOL, and the CATALYS c0s 6 software, with features for improved astigmatism management workflow, in Europe.
- CLEAR (Corneal Lenticule Extraction for Advanced Refractive Correction), an application integrated in Ziemer’s FEMTO LDV Z8, received the CE mark.
- Micro Labs USA, a producer of generic medicines with FDA-approved facilities in India, announced its launch of dorzolamide HCL ophthalmic solution, 2%, and dorzolamide-timolol maleate ophthalmic solution, 22.3mg/6.8 mg/mL.
- Konan Medical and Konan Medical USA launched CellChek 20, an endothelial imaging system that is FDA approved and CE marked.
This issue of EyeWorld Weekly was edited by Stacy Jablonski and Vanessa Caceres.
EyeWorld Weekly (ISSN 1089-0319), a digital publication of the American Society of Cataract and Refractive Surgery (ASCRS), is published every Friday, distributed by email, and posted live on Friday.
Medical Editors: Eric Donnenfeld, MD, Chief Medical Editor; Rosa Braga-Mele, MD, Cataract Editor; Clara Chan, MD, Cornea Editor; Nathan Radcliffe, MD, Glaucoma Editor; and Vance Thompson, MD, Refractive Editor
For sponsorship opportunities or membership information, contact: ASCRS • 4000 Legato Rd. • Suite 700 • Fairfax, VA 22033 • Phone: 703-591-2220 • Fax: 703-591-0614 • Email: ASCRS Opinions expressed in EyeWorld Weekly do not necessarily reflect those of ASCRS. Mention of products or services does not constitute an endorsement by ASCRS.
Click here to view our Legal Notice.
Copyright 2021, EyeWorld News Service, a division of ASCRSMedia. All rights reserved.